IL-WALGREENS-BOOTS
Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced its decision to keep its Boots and No7 Beauty Company businesses under its existing ownership. This marks the conclusion of the review that began in January in line with the Company’s strategic priorities.
WBA has been encouraged by productive discussions held with a range of parties, receiving significant interest from prospective buyers. However, since launching the process, the global financial markets have suffered unexpected and dramatic change. As a result of market instability severely impacting financing availability, no third party has been able to make an offer that adequately reflects the high potential value of Boots and No7 Beauty Company. Consequently, WBA has decided that it is in the best interests of shareholders to keep focusing on the further growth and profitability of the two businesses.
The decision to retain the businesses has also been supported by the ongoing strong performance and growth of Boots and No7 Beauty Company, which have exceeded expectations despite challenging conditions.
Boots is the UK’s leading health and beauty retailer and benefits from its unique position as one of the most trusted and well-respected brands in the country. Since the formation of WBA at the end of 2014, the Company has significantly invested in Boots and No7 Beauty Company. Given their unmatched assets and unparalleled potential, Walgreens Boots Alliance will continue investing in the future of these two businesses.
Chief Executive Officer, Rosalind Brewer, said:
“We have now completed a thorough review of Boots and No7 Beauty Company, with the outcome reflecting rapidly evolving and challenging financial market conditions beyond our control. It is an exciting time for these businesses, which are uniquely positioned to continue to capture future opportunities presented by the growing healthcare and beauty markets. The Board and I remain confident that Boots and No7 Beauty Company hold strong fundamental value, and longer term, we will stay open to all opportunities to maximize shareholder value for these businesses and across our company.”
About Walgreens Boots Alliance
Walgreens Boots Alliance (Nasdaq: WBA) is an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 170-year heritage of caring for communities.
A trusted, global innovator in retail pharmacy with approximately 13,000 locations across the U.S., Europe and Latin America, WBA plays a critical role in the healthcare ecosystem. The company is reimagining local healthcare and well-being for all as part of its purpose – to create more joyful lives through better health. Through dispensing medicines, improving access to a wide range of health services, providing high quality health and beauty products and offering anytime, anywhere convenience across its digital platforms, WBA is shaping the future of healthcare.
WBA has more than 315,000 team members and a presence in nine countries through its portfolio of consumer brands: Walgreens, Boots, Duane Reade, the No7 Beauty Company, Benavides in Mexico and Ahumada in Chile. Additionally, WBA has a portfolio of healthcare-focused investments located in several countries, including China and the U.S.
The company is proud of its contributions to healthy communities, a healthy planet, an inclusive workplace and a sustainable marketplace. WBA has been recognized for its commitment to operating sustainably: it is an index component of the Dow Jones Sustainability Indices (DJSI) and was named to the 100 Best Corporate Citizens 2021.
More company information is available at www.walgreensbootsalliance.com .
(WBA-GEN)
Cautionary Note Regarding Forward-Looking Statements: All statements in this release that are not historical are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including those described in Item 1A (Risk Factors) of our Form 10-K for the fiscal year ended August 31, 2021 and in other documents that we file or furnish with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. These forward-looking statements speak only as of the date they are made. We do not undertake, and expressly disclaim, any duty or obligation to update publicly any forward-looking statement after the date of this release, whether as a result of new information, future events, changes in assumptions or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220628005512/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
“All Genetic Diseases Could be Cured within a Decade”, Hears Dubai Future Forum20.11.2025 14:15:00 CET | Press release
All known genetic diseases could be cured within the next decade thanks to major advances in gene editing, a leading scientist told the Dubai Future Forum 2025. Discussing his company’s research, Dr. Trevor Martin, Co-founder and CEO of Mammoth Biosciences, described “a one-time cure that will reshape the healthcare system as we know it.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120548681/en/ Dubai Future Forum 2025 (Photo: AETOSWire) Opening the forum, Khalfan Belhoul, CEO of Dubai Future Foundation, introduced the concept of “national cognitive potential”, arguing that countries in the future will gain a competitive edge in fields like AI by leveraging the collective cognitive strength of their societies. In another session, Dr. Nikku Madhusudhan, Professor of Astrophysics at the University of Cambridge, said there is a “good chance” humanity will discover life on another planet—possibly in the next decade. He exp
12 Major Verification Trends in 2026: Regula on the Birth of a New Digital Identity20.11.2025 14:00:00 CET | Press release
How we verify is changing — and so is who and what we verify. Are we dealing with real people, fraudsters, or machines acting on their behalf? A new Regula report on 12 identity verification trendsexamines how these shifts are forcing businesses to rebuild their verification processes to stay ahead of fraud, comply with regulations, and regain eroding customer confidence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120373343/en/ Identity is leaving the human domain: Regula’s forecast illustrates the emerging need to verify systems, autonomous agents, and machine customers. The new face of fraud The identity threat landscape has entered a new industrial phase, defined by three structural shifts: Machine identity. Identity verification (IDV) is no longer limited to people. It now extends to autonomous systems acting on their behalf — AI agents that can open accounts, submit documents, and bypass checks on their own. Frau
Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies20.11.2025 14:00:00 CET | Press release
AI-driven genomic foundation model integrates wet-lab validation, population-scale genomics, and advanced machine learning to improve gene editing design at scale Founding team unites CRISPR pioneers and AI leaders, supported by a world-class Scientific Advisory Board including Dr. Vic Myer (former CTO, Editas Medicine) and Dr. Saar Gill (UPenn) Cassidy Bio, a biotechnology company developing the first AI-driven genomic foundation model to enhance the design of gene editing therapies, today announced its launch and the closing of an $8 million seed financing round. The company will use the funding to advance its platform, built as a holistic solution designed to bring precision, speed, and clinical confidence to the rapidly growing field of gene therapies. Cassidy Bio’s AI-driven genomic foundation model combines proprietary wet-lab data, population-scale genomic insights, and advanced machine learning to predict the best pairings of guides, enzymes, and delivery modalities, matching t
Scientist.com Completes Acquisition by GHO Capital Partners to Accelerate Global R&D Orchestration20.11.2025 13:55:00 CET | Press release
Strategic partnership finalized, unlocking expanded AI-driven platform capabilities and international growth Scientist.com, the life sciences industry’s leading AI-enabled R&D orchestration platform, and GHO Capital Partners LLP (“GHO”), the specialist private equity investor in global healthcare, today announced the successful closing of GHO’s acquisition of Scientist.com. The transaction marks the beginning of an accelerated expansion phase, strengthening Scientist.com’s mission to transform pharmaceutical R&D by streamlining the entire outsourced research lifecycle. “This is a pivotal moment for Scientist.com and for the global research community we support,” said Kevin Lustig, CEO and Chris Petersen, CTO, the founders of Scientist.com. “Partnering with GHO, a team that shares our vision and brings deep expertise in scaling healthcare technology companies, enables us to invest aggressively in our AI-powered orchestration platform and expand our global footprint. Together, we are bet
SimpliStor™ Solid State Data Recorder Delivers High-Speed, Radiation-Tolerant Storage for Next-Generation Space Missions20.11.2025 13:00:00 CET | Press release
Frontgrade™ Technologies, a leading provider of high-reliability electronic solutions for space and national security missions, today announced the release of the SimpliStor™ Solid State Data Recorder (SSDR), a next-generation, radiation-tolerant data recorder that gives satellite operators, system integrators, and spacecraft designers a faster, smarter, and more resilient way to capture and protect mission-critical information in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120514203/en/ Frontgrade's SimpiStor™ 2.5TB Solid-State Data Recorder High-Throughput Performance SimpliStor delivers 2.5 terabytes of storage and 10Gbps throughput in a compact 3U SpaceVPX package, combining exceptional performance with low power consumption. Users can record more data in less time, with latency under 100 microseconds and continuous “store-to-full” recording, ensuring no data loss during peak operations. A 33-minute continuo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
